MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-22-2023
Nabriva Therapeutics plc Total Shareholders Equity 2011-2026 | NBRV
Annual Total Shareholders Equity Nabriva Therapeutics plc
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.29 M | 53.4 M | 33.1 M | 41.3 M | 68.6 M | 82.1 M | 77.3 M | 109 M | -29 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | -29 M | 48.7 M |
Quarterly Total Shareholders Equity Nabriva Therapeutics plc
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.36 M | 3.29 M | 25.6 M | 34.6 M | 44.6 M | 53.4 M | 63.3 M | 69.2 M | 55 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 41.3 M | 41.3 M | 41.3 M | 41.3 M | 68.6 M | 68.6 M | 68.6 M | 68.6 M | 82.1 M | 82.1 M | 82.1 M | 82.1 M | 77.3 M | 77.3 M | 77.3 M | 77.3 M | 109 M | - | - | - | -29 M | - | - | - | -18.6 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | -29 M | 50.5 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Verastem
VSTM
|
57.2 M | $ 5.04 | -4.73 % | $ 349 M |  USA |
 |
VistaGen Therapeutics
VTGN
|
70.4 M | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
219 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Xenon Pharmaceuticals
XENE
|
755 M | $ 54.48 | -1.89 % | $ 4.24 B |  Canada |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
 |
Enochian Biosciences
ENOB
|
-21.3 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
659 M | $ 16.58 | -3.94 % | $ 12.4 B | Britain |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
76.6 M | $ 4.29 | -3.6 % | $ 822 M | Canada |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
8.38 M | - | -10.95 % | $ 876 K | USA |
 |
Fusion Pharmaceuticals
FUSN
|
222 M | - | - | $ 1.41 B | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 19.01 | -2.66 % | $ 889 M | USA |
 |
Gritstone Oncology
GRTS
|
51.8 M | - | 0.42 % | $ 213 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
733 M | $ 20.75 | -3.35 % | $ 3.44 B | USA |
 |
Aligos Therapeutics
ALGS
|
53.5 M | $ 6.66 | -5.4 % | $ 65.8 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alkermes plc
ALKS
|
1.82 B | $ 29.39 | -1.77 % | $ 4.84 B |  Irlanda |
 |
Cabaletta Bio
CABA
|
112 M | $ 2.68 | -4.96 % | $ 269 M | USA |
 |
AbbVie
ABBV
|
-3.27 B | $ 209.4 | -0.81 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Athira Pharma
ATHA
|
44.8 M | - | - | $ 269 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |